Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M-positive non-small cell lung cancer.

Hye Sook KimKun Young LimSoo-Hyun LeeHyae Young KimYoungjoo LeeJi-Youn Han

Published in: Cancer medicine (2023)

PD during osimertinib treatment occurred preferentially in the thorax and pre-existing sites. Extracranial PD prevailed over intracranial PD regardless of baseline BM and prior brain radiation. These results support osimertinib's intracranial efficacy and may guide treatment strategies for EGFR-mutated NSCLC with BM.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
brain metastases
tyrosine kinase
optic nerve
internal carotid artery
resting state
functional connectivity
combination therapy
brain injury
subarachnoid hemorrhage